002788 鹭燕医药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)6.86211.31712.83013.24312.554
总资产报酬率 ROA (%)1.7112.8293.0843.1703.295
投入资产回报率 ROIC (%)2.1993.6654.0514.1544.341

边际利润分析
销售毛利率 (%)6.9567.4477.6047.7857.815
营业利润率 (%)1.8282.2382.3612.3942.313
息税前利润/营业总收入 (%)2.6953.2483.4893.5253.457
净利润/营业总收入 (%)1.3781.6991.8371.8031.736

收益指标分析
经营活动净收益/利润总额(%)107.244103.627103.549110.971105.120
价值变动净收益/利润总额(%)-3.776-4.132-2.590-1.485-0.514
营业外收支净额/利润总额(%)-0.522-1.0640.1840.0142.248

偿债能力分析
流动比率 (X)1.0991.1471.1611.1741.186
速动比率 (X)0.8020.8140.8400.8670.862
资产负债率 (%)74.97574.74574.75876.31874.380
带息债务/全部投入资本 (%)66.33065.91164.99067.05465.077
股东权益/带息债务 (%)48.20848.74650.25745.45349.790
股东权益/负债合计 (%)33.13433.47533.41730.25433.524
利息保障倍数 (X)3.0743.1423.1063.1183.170

营运能力分析
应收账款周转天数 (天)105.967101.460104.071100.80592.155
存货周转天数 (天)51.37551.67250.28748.37747.889